NOK

NOK Therapeutics is a clinical-stage biotechnology company pioneering a new paradigm in cancer care through the development of autologous, non-engineered natural killer (NK) cell therapies. The company's platform is designed to restore the body's first line of immune defense without the need for lymphodepletion, a common and harsh requirement for traditional cell therapies. By eliminating high-dose chemotherapy, NOK's approach aims to provide a safer, more accessible, and outpatient-friendly treatment option. Their lead programs target high-relapse oncology indications, specifically multiple myeloma and urothelial cancer, focusing on deepening remissions and driving cures. Led by industry veterans with extensive experience in pharmaceutical development, NOK is positioned to fill a critical gap in the current immunotherapy landscape.